non-financial development institution
major organizer of congress and exhibition events
Восстановление пароля
Введите адрес электронной почты или телефон, указанные при регистрации. Вам будет отправлена инструкция по восстановлению пароля.
Некорректный формат электронной почты или телефона
Кукава Вадим

Vadim Kukava

Executive Director, Innovative Pharma Association of Pharmaceutical Companies
SPIEF 2019
Priority Strategies in the Supply of Drugs
The innovation industry. The development of regulation in this area will depend on the development of the pharma industry. In terms of foreign investors, much will depend on whether they will bring innovative medicines to the Russian market, whether they will invest in clinical research, and whether they will invest in production facilities
SPIEF 2019
Priority Strategies in the Supply of Drugs
As the regulatory framework for pharma develops, it often runs counter to and even destroys those lofty and fitting goals stated in strategy documents
SPIEF 2019
Innovative development of the pharmaceutical and biotech industry in Russia: keys to success
Contradictions appear on the legislative level. Because, on one hand, we say we need to develop Russian innovations, while, on the other hand, we have what we have when it comes to intellectual property protection in the pharmaceutical industry. <…> There is an enormous pressure as far as pricing is concerned
Healthy Life Forum: Towards 80+ 2019
A System of Universal Medicine Provision: Key to Achieving the National Goal
If we implement universal medicine provision, which is now being openly discussed by the Ministry of Health, when it comes to those diseases that are most common in Russia: cardiovascular, musculoskeletal, and respiratory diseases, when it comes to 10 illnesses that are currently not being covered, in the next 10 years we could expect to see the mortality rate of those diseases drop by 10% and see an annual 0.8% boost to the GDP